TI
KLRS

Trexquant Investment’s Kalaris Therapeutics KLRS Stock Holding History

Trexquant Investment’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,956
Closed -$349K – 1846
2022
Q4 		$349K Buy
+2,956
New +$501K 0.01% 1051
2022
Q3 		– Sell
-660
Closed -$59K – 1907
2022
Q2 		$59K Buy
+660
New +$69.2K ﹤0.01% 1462
2022
Q1 		– Sell
-1,548
Closed -$461K – 1802
2021
Q4 		$461K Buy
+1,548
New +$718K 0.03% 688
2021
Q2 		– Sell
-488
Closed -$263K – 1570
2021
Q1 		$263K Buy
+488
New +$410K 0.02% 818

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Trexquant Investment's KLRS Position: Q1 2023 in Review

Trexquant Investment sold out of Kalaris Therapeutics (KLRS) in Q1 2023, closing a stake of 2,956 shares — an estimated $349K sold.

Trexquant Investment first reported a position in KLRS in Q1 2021 and held it in 4 quarters. The position peaked at $461K in Q4 2021. 89 funds tracked by Wall St. Rank hold KLRS as of Q1 2023.

  • Trexquant Investment reported no remaining Kalaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Trexquant Investment sold 2,956 Kalaris Therapeutics shares in Q1 2023, an estimated $349K.
  • Trexquant Investment first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 4 quarters.
  • Trexquant Investment's Kalaris Therapeutics position peaked at $461K in Q4 2021.
  • 89 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2023.

Based on Trexquant Investment's 13F filing for Q1 2023, filed 15 May 2023.